Wedbush Comments on Ardelyx's Q4 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Wedbush raised their Q4 2025 earnings estimates for shares of Ardelyx in a research report issued to clients and investors on Friday, May 2nd. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of $0.01 per share for the quarter, up from their previous forecast of ($0.01). The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's FY2026 earnings at $0.08 EPS and FY2029 earnings at $0.89 EPS.

ARDX has been the topic of a number of other reports. LADENBURG THALM/SH SH reissued a "buy" rating and issued a $11.00 price target on shares of Ardelyx in a research note on Friday, March 7th. StockNews.com lowered Ardelyx from a "hold" rating to a "sell" rating in a research report on Monday. Piper Sandler upgraded Ardelyx to a "hold" rating in a research report on Wednesday, March 12th. Raymond James downgraded Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 price objective on the stock. in a report on Friday, May 2nd. Finally, HC Wainwright restated a "neutral" rating and set a $5.50 target price on shares of Ardelyx in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Ardelyx has a consensus rating of "Moderate Buy" and an average target price of $10.39.

Ardelyx Trading Down 1.6 %

ARDX traded down $0.06 on Monday, hitting $3.58. The company had a trading volume of 1,517,731 shares, compared to its average volume of 4,855,288. The company's fifty day moving average price is $4.89 and its 200 day moving average price is $5.20. Ardelyx has a 1 year low of $3.50 and a 1 year high of $8.14. The company has a current ratio of 4.58, a quick ratio of 4.31 and a debt-to-equity ratio of 0.87. The firm has a market cap of $856.53 million, a P/E ratio of -22.38 and a beta of 0.76.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.07). The business had revenue of $74.11 million during the quarter, compared to analysts' expectations of $79.40 million. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. Ardelyx's revenue for the quarter was up 61.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.11) EPS.

Hedge Funds Weigh In On Ardelyx

Several large investors have recently bought and sold shares of ARDX. Blair William & Co. IL boosted its position in shares of Ardelyx by 67.6% during the 1st quarter. Blair William & Co. IL now owns 24,785 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 10,000 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in Ardelyx by 6.4% in the first quarter. Mackenzie Financial Corp now owns 149,158 shares of the biopharmaceutical company's stock valued at $732,000 after purchasing an additional 9,025 shares in the last quarter. Caliber Wealth Management LLC KS acquired a new position in Ardelyx in the first quarter valued at approximately $99,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Ardelyx in the first quarter valued at approximately $2,085,000. Finally, CWM LLC raised its holdings in Ardelyx by 4,554.4% during the first quarter. CWM LLC now owns 79,777 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 78,063 shares in the last quarter. Hedge funds and other institutional investors own 58.92% of the company's stock.

Insider Activity

In other news, Director David M. Mott acquired 77,729 shares of the company's stock in a transaction on Monday, February 24th. The shares were bought at an average cost of $5.00 per share, with a total value of $388,645.00. Following the transaction, the director now owns 2,015,494 shares in the company, valued at approximately $10,077,470. This trade represents a 4.01 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Raab sold 22,964 shares of Ardelyx stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total transaction of $129,057.68. Following the sale, the chief executive officer now directly owns 1,085,755 shares of the company's stock, valued at approximately $6,101,943.10. This trade represents a 2.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,076 shares of company stock worth $777,555. 5.90% of the stock is currently owned by company insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.